LUMOS-DIAGNOSTICS
6.10.2020 23:52:11 CEST | Business Wire | Press release
Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
The funding will enable Lumos, headquartered in Melbourne, to continue to build its high-growth rapid diagnostics business in the U.S., including expanding manufacturing operations in California and Florida and continuing commercial growth of its FebriDx® product, a world-first finger prick blood test that can indicate if a person has a bacterial or viral infection within 10 minutes.
The capital was raised from a combination of institutional funds, including Perennial Value and Ellerston Capital, and sophisticated investors, many of whom have backed Lumos through previous capital raises. It follows on from a successful Series A raise in early 2020, led by Planet Innovation , a Melbourne-based healthcare innovation company.
“Lumos has built a strong foundation over the past few years, and this funding will enable us to accelerate our growth plan,” said Sam Lanyon, executive chair of Lumos Diagnostics. “We’re delighted that investors recognize how unique Lumos is with its suite of rapid diagnostic digital solutions coupled with high-impact and globally relevant proprietary products such as FebriDx.”
David Keelan, Portfolio Manager at Ellerston Capital and a first-time Lumos investor, said: “I’m really excited by Lumos’s potential. Rapid diagnostics is a developing sector internationally, and to have a really strong and growing service business, complemented by a product business with huge potential – it was too good an investment to pass up.”
Ryan Sohn, Deputy Portfolio Manager at Perennial Value, was introduced to Lumos Diagnostics through Planet Innovation (PI), where he is also an investor. “Through PI, I’ve been able to track Lumos’s substantial growth over the past few years. It’s a company with great ambition and a great team behind it, and I’m excited to be a part of this next phase of growth as it prepares for an IPO next year,” Ryan said.
While many businesses have been negatively impacted by the devastating global impacts of the COVID-19 crisis, Lumos was well positioned to quickly respond and has subsequently experienced growth across both its service and product businesses. On the service side, Lumos has secured several contracts to develop and manufacture next generation rapid SARS-CoV-2 tests. On the product side, the UK’s National Institute of Health Research (NIHR) has demonstrated real-world use of the FebriDx test as a frontline triage tool to help healthcare workers manage suspected COVID-19 infected patients. The FebriDx test was featured in a UK Medtech Innovation Briefing (MIB) , addressing the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises. Also, FebriDx may be used as an important risk assessment tool for safe workplaces and is currently being piloted in aged care and other professional use settings continuing to operate during the pandemic.
Robert Sambursky, MD, president and chief executive officer for Lumos Diagnostics, said the capital raise would enable Lumos to expand its commercial operations dedicated to both the continued development of rapid point-of-care diagnostics and meet the need for innovative testing solutions to help address the global COVID-19 pandemic.
“The unique ability of the FebriDx test to identify patients as viral or bacterial within 10 minutes helps guide clinical decision making – whether that is isolation for those identified as having a virus, antibiotic prescriptions for bacterial infections, or simply reassurance that an infection is not present. These actionable results make FebriDx the ideal front-line triage test for patients presenting with acute respiratory illness symptoms (sore throat, cough, shortness of breath) consistent with COVID-19 and an ideal tool for rapid deployment in any future pandemics,” Sambursky said.
While FebriDx is not yet commercially available in the U.S., Lumos Diagnostics has both ongoing and historic prospective, multicenter U.S. clinical trials and anticipates U.S. Food and Drug Administration (FDA) clearance.
Blackpeak Capital acted as Financial Advisor to Lumos and Joint Lead Manager for the raising alongside Canaccord Genuity.
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs.
Lumos’s current portfolio of tests includes:
- FebriDx®, an all-in-one, disposable, 10-minute, fingerstick blood test that differentiates viral from bacterial acute respiratory infections (ARI).
- COV-ID™; the Diagnostic Kit (Colloidal Gold) for IgG/IgM Antibody to SARS-CoV-2, a rapid and easy-to-use serology test for the qualitative detection of antibodies to SARS-CoV-2 virus in patients suspected of a history of COVID-19 infection.
Both the FebriDx and COV-ID tests are CE marked for sale in Europe. FebriDx is also registered or licensed with the following other health authorities: Health Canada, Australia TGA, Saudi Arabia FDA, Pakistan DRAP, Singapore HSA, and Malaysia MoH. COV-ID is available in specific global markets in compliance with country requirements. The FebriDx test has not received U.S. FDA clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit lumosdiagnostics.com , and for more information on FebriDx, visit febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe17.11.2026 09:00:00 CET | Press release
European Technology Group (ETG), a long-term oriented European GovTech platform, welcomes Tractivity, a leading stakeholder relationship management software provider in Europe, to its family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117911743/en/ Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe The transaction marks the next stage of Tractivity’s development after sustained growth. The company serves more than 100 organisations across energy, utilities, healthcare, central and local government, regulators and transport in Europe. As part of ETG, Tractivity will build on its established brand, long-standing customer trust and clear product focus. ETG adds resources and know-how to accelerate product development and invest in AI capabilities that make stakeholder engagement more efficient. ETG’s European network will support Tractivity’s expansion across Europe and among en
Aqara Expands Smart Lighting Portfolio, Showing the Spatial Intelligence Control With the Lighting Transfer17.11.2026 09:00:00 CET | Press release
Six new lighting products bring vibrant indoor and outdoor illumination, seamless Apple Home compatibility, dual-protocol connection, and personalized automation powered by Aqara numerous portfolio Aqara, a global leader and pioneer in IoT, today announced the global launch of six new smart lighting products showcased at IFA 2026: the Floor Lamp T1, LED Downlight T2, LED Strip T2, LED Bulb T2 E12/E14, Outdoor String Lights H1, and Permanent Outdoor Lights H1. Spanning everyday illumination, immersive entertainment, and outdoor decoration, the expanded portfolio pairs advanced lighting technology and flexible connectivity with Aqara’s extensive range of smart home devices to create more responsive, personalized living spaces. Together, they bring Aqara’s vision of Spatial Intelligence into the home. In addition, all these six products can be seamlessly integrated into the Apple Home ecosystem, offering smooth across-platform usage experience. This press release features multimedia. View
FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 07:30:00 CET | Press release
Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
